GeoVax Labs (GOVX) Competitors $0.66 -0.02 (-2.72%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GOVX vs. IPSC, TELO, BRNS, GRCE, ATHE, LTRN, BCAB, LVTX, CALC, and ESLAShould you be buying GeoVax Labs stock or one of its competitors? The main competitors of GeoVax Labs include Century Therapeutics (IPSC), Telomir Pharmaceuticals (TELO), Barinthus Biotherapeutics (BRNS), Grace Therapeutics (GRCE), Alterity Therapeutics (ATHE), Lantern Pharma (LTRN), BioAtla (BCAB), LAVA Therapeutics (LVTX), CalciMedica (CALC), and Estrella Immunopharma (ESLA). These companies are all part of the "pharmaceutical products" industry. GeoVax Labs vs. Its Competitors Century Therapeutics Telomir Pharmaceuticals Barinthus Biotherapeutics Grace Therapeutics Alterity Therapeutics Lantern Pharma BioAtla LAVA Therapeutics CalciMedica Estrella Immunopharma Century Therapeutics (NASDAQ:IPSC) and GeoVax Labs (NASDAQ:GOVX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings. Which has higher earnings & valuation, IPSC or GOVX? GeoVax Labs has lower revenue, but higher earnings than Century Therapeutics. Century Therapeutics is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCentury Therapeutics$6.59M6.65-$126.57M-$0.29-1.75GeoVax Labs$3.95M2.67-$24.99M-$2.01-0.33 Do institutionals & insiders have more ownership in IPSC or GOVX? 50.2% of Century Therapeutics shares are owned by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are owned by institutional investors. 5.0% of Century Therapeutics shares are owned by company insiders. Comparatively, 1.2% of GeoVax Labs shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media prefer IPSC or GOVX? In the previous week, GeoVax Labs had 2 more articles in the media than Century Therapeutics. MarketBeat recorded 2 mentions for GeoVax Labs and 0 mentions for Century Therapeutics. GeoVax Labs' average media sentiment score of 0.06 beat Century Therapeutics' score of 0.00 indicating that GeoVax Labs is being referred to more favorably in the news media. Company Overall Sentiment Century Therapeutics Neutral GeoVax Labs Neutral Which has more risk and volatility, IPSC or GOVX? Century Therapeutics has a beta of 1.78, meaning that its stock price is 78% more volatile than the S&P 500. Comparatively, GeoVax Labs has a beta of 3.57, meaning that its stock price is 257% more volatile than the S&P 500. Is IPSC or GOVX more profitable? Century Therapeutics has a net margin of -19.10% compared to GeoVax Labs' net margin of -403.88%. Century Therapeutics' return on equity of -11.53% beat GeoVax Labs' return on equity.Company Net Margins Return on Equity Return on Assets Century Therapeutics-19.10% -11.53% -6.94% GeoVax Labs -403.88%-408.80%-279.89% Do analysts prefer IPSC or GOVX? Century Therapeutics presently has a consensus target price of $3.75, suggesting a potential upside of 639.64%. GeoVax Labs has a consensus target price of $8.50, suggesting a potential upside of 1,184.96%. Given GeoVax Labs' higher possible upside, analysts clearly believe GeoVax Labs is more favorable than Century Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Century Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00GeoVax Labs 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryCentury Therapeutics beats GeoVax Labs on 9 of the 15 factors compared between the two stocks. Get GeoVax Labs News Delivered to You Automatically Sign up to receive the latest news and ratings for GOVX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GOVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GOVX vs. The Competition Export to ExcelMetricGeoVax LabsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.83M$3.12B$5.76B$10.29BDividend YieldN/A2.37%5.74%4.63%P/E Ratio-0.3321.2276.8626.97Price / Sales2.67462.32540.67127.61Price / CashN/A45.3237.1760.63Price / Book1.389.6913.836.37Net Income-$24.99M-$52.92M$3.29B$271.46M7 Day Performance-7.68%1.44%0.93%2.35%1 Month Performance-10.61%6.03%5.31%7.78%1 Year Performance-75.41%12.89%84.25%32.27% GeoVax Labs Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GOVXGeoVax Labs1.7731 of 5 stars$0.66-2.7%$8.50+1,185.0%-75.1%$10.83M$3.95M-0.3310News CoverageShort Interest ↑Gap UpIPSCCentury Therapeutics1.853 of 5 stars$0.50-0.7%$3.75+654.2%-70.4%$42.95M$6.59M-1.71170TELOTelomir Pharmaceuticals2.101 of 5 stars$1.33-2.2%$15.00+1,027.8%-76.3%$42.93MN/A-2.461BRNSBarinthus Biotherapeutics2.1211 of 5 stars$1.05-4.5%$3.00+185.7%-14.4%$42.76M$14.97M-0.61107Positive NewsGRCEGrace Therapeutics2.9036 of 5 stars$3.07-2.5%$12.00+290.9%N/A$42.46MN/A-3.57N/ANews CoverageATHEAlterity Therapeutics2.017 of 5 stars$4.64-4.9%$12.00+158.6%+247.9%$41.16MN/A0.0010LTRNLantern Pharma2.0546 of 5 stars$3.81-0.5%$25.00+556.2%+2.6%$41.15MN/A-2.1420BCABBioAtla0.5689 of 5 stars$0.69-10.3%$5.00+619.5%-59.7%$40.81M$11M-0.6360LVTXLAVA Therapeutics1.5657 of 5 stars$1.54-0.3%$2.69+74.4%-14.8%$40.52M$11.98M-1.4760Negative NewsInsider TradeShort Interest ↑CALCCalciMedica2.7322 of 5 stars$2.85-10.1%$16.00+461.4%-18.2%$39.81MN/A-1.7830Positive NewsHigh Trading VolumeESLAEstrella Immunopharma2.0928 of 5 stars$1.07+1.4%$16.00+1,402.3%+30.4%$39.48MN/A-4.10N/AGap Up Related Companies and Tools Related Companies IPSC Competitors TELO Competitors BRNS Competitors GRCE Competitors ATHE Competitors LTRN Competitors BCAB Competitors LVTX Competitors CALC Competitors ESLA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GOVX) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredDid you spot this in the Oval Office last week?When Tim Cook stood in the Oval Office last week, all eyes were on the "unique 24K gold gift" he presented to ...InvestorPlace | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeoVax Labs Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GeoVax Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
